Efficacy and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in pulmonary sarcomatoid carcinoma

Efficacy and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic pulmonary sarcomatoid carcinoma: a retrospective cohort study - Efficacy and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic pulmonary sarcomatoid carcinoma: a retrospective cohort study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046002

Enrollment

150

Registered

2022-01-01

Start date

2022-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary sarcomatoid carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with histologically or cytologically proven PSC (2) Patients with stage IIIB/IIIC/IV or postoperative recurrence (3) Patients who received ICI alone or in combination with chemotherapy (4) Patients aged 20 years or older at the time of diagnosis

Exclusion criteria

Exclusion criteria: (1)Patients who chose not to participate in the study (2)Patients who received ICI as previous therapy

Design outcomes

Primary

Measure	Time frame
Overall Response Rate, Progression Free Survival	—

Countries

Japan

Contacts

Public ContactDaisuke Hazama

Kobe University Graduate School of Medicine Division of Respiratory Medicine, Department of Internal Medicine

dhazama@med.kobe-u.ac.jp078-382-5660

Outcome results